Videos

Introducing integrated palliative care to patients with a certain type of leukemia was shown to facilitate active coping strategies, which could improve a patient’s quality of life.

Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.

Drs Benjamin Levy and Lori J. Wirth describe how they currently utilize comprehensive genomic profiling to manage patients with non–small cell lung cancer or thyroid cancer.

Responses to the study drug, according to one of the study’s authors, appeared far superior than what would have been expected with other treatments in patients with HER2-expressing metastatic colorectal cancer.

Although recent data show how promising a single-infusion of a specific CAR-T cell therapy may be for patients with acute lymphoblastic leukemia, an expert from the Moffitt Cancer Center notes that more research is needed for those deemed too ill to receive the treatment.

The data, according to one of the study’s authors, are critical in understanding the disparities in prostate cancer.

Yanghee Woo, M.D., comments on disparities in healthcare for select patients with gastric cancer and describes how these impact the diagnosis and treatment of the disease.

City of Hope’s Yanghee Woo, M.D., highlights risk factors for gastric cancer and comments on the rise in cases in adults 40 years of age and younger.

The Tigerlily Foundation and Guiding Researchers and Advocates for Scientific Partnerships (GRASP) November conversation focused on what it means to have “Cancer While Black: Moving Past the Medical Mistrust Impact."

Donna and Dr Gasparetto close the discussion by highlighting the importance of physicians utilizing their patients, as well as patients being involved with their multiple myeloma treatment.

Donna gives advice to other multiple myeloma patients about what she has learned from living with this disease and her various therapies.

Lori J. Wirth, MD, of Massachusetts General Hospital, comments on the role of molecular testing to guide treatment decisions in thyroid cancer and explains how personalized medicine differs from standard treatment approaches.

Benjamin Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, describes how molecular testing in non–small cell lung cancer has advanced and impacted treatment.

Ask the Experts is a question and answer session with two of the leading bladder cancer experts in the United States, Kent Mouw, MD, PhD and Sarah P Psutka, MD, MSc.

The Tigerlily Foundation and GRASP presents a conversation with Dr. Tisha M. Felder on what it means to have “Cancer While Black: How Trauma, Fear, Generational Pain & Mistrust Impact Breast Cancer.”

View the full CURE® Educated Patient® Webinar: Empowering Patients to Understand Cancer Genetic Testing and Counseling on demand.

Cristina Gasparetto, MD, discusses Donna’s next line of therapy, selinexor, and how being part of a clinical trial impacted her multiple myeloma.

Donna’s multiple myeloma treatment changes with the help of Dr Cristina Gasparetto’s direct influence and CAR T cell therapy.

Cristina Gasparetto, MD, discusses Donna’s relationship with the drug carfilzomib for multiple myeloma therapy, as well as her second relapse.

Donna and Dr Gasparetto converse about the many first- and second-line therapies for multiple myeloma.

Cristina Gasparetto, MD, details typical multiple myeloma maintenance in comparison with Donna’s therapies, and Donna tells us about her first relapse with multiple myeloma.

We learn more about Donna’s 2 transplants, her chemotherapy, and how they impacted her quality of life.

Donna discusses her multiple myeloma diagnosis and the start of her treatment, while Dr Gasparetto educates on the importance of transplants.

Cristina Gasparetto, MD, gives a brief overview of the multiple myeloma disease state and introduces us to Donna, one of her patients diagnosed with multiple myeloma.

Patients with cancer can advocate for themselves by researching their illnesses and treatments before an appointment, so they’re able to ask better questions, says an expert from the HealthTree Foundation for Multiple Myeloma.

An expert thoracic oncologist, Adam J. Schoenfeld, MD, highlights key factors that patients and providers should take into account when considering cell therapy in non–small cell lung cancer.

A key opinion leader in the management of lung cancer offers insight into ongoing clinical trials of tumor-infiltrating lymphocyte (TIL) therapy in non–small cell lung cancer.

New advances in research around immunotherapies for patients with myeloma are on the horizon, according to an expert from the HealthTree Foundation & Myeloma Crowd.